The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight

Posted on by sHq_LoGiNz

With the emergence of novel therapies and expanded indications, the United States IL-2 market is projected to reach USD 4 billion by 2034. Key players driving this expansion include Iovance Biotherapeutics, Eisai, Citius Pharmaceuticals, Nektar Therapeutics, Mural Oncology, Corvus…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.